Results 121 to 130 of about 146,874 (392)

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.

JAMA Oncology, 2020
Importance Prospective assessment of treatments known to benefit patients in global clinical trials in specific racial groups is essential. Objective To compare the efficacy, safety, and tolerability of adding pertuzumab to trastuzumab and docetaxel vs
Z. Shao, D. Pang, Hongjian Yang, Wei Li, Shusen Wang, S. Cui, N. Liao, Yongsheng Wang, Chuanwang Wang, Yuan-Ching Chang, Hwei‐Ming Wang, S. Kang, J. Seo, K. Shen, Suphawat Laohawiriyakamol, Zefei Jiang, Junjie Li, Julian Zhou, B. Althaus, Y. Mao, J. Eng-Wong   +20 more
semanticscholar   +1 more source

Real‐world treatment patterns among patients diagnosed with hormone receptor‐positive metastatic breast cancer in the USA

British Journal of Clinical Pharmacology, EarlyView.
Aims Clinical guidelines for breast cancer management have evolved in the past decade. However, limited evidence exists regarding uptake of novel drug classes in management of hormone receptor‐positive (HR+) metastatic breast cancer (MBC) in the USA and whether disparities exist by race and ethnicity.
Kexin Zhu, Coral O. Omene, Antoinette Stroup, Elisa V. Bandera, Farzin Khosrow‐Khavar   +4 more
wiley   +1 more source

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study [PDF]

, 2018
BackgroundThis phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.MethodsPatients were enrolled in four cohorts: MM-302 ...
Adiwijaya, Bambang S, Campbell, Karen, Geretti, Elena, Hendriks, Bart S, Krop, Ian E, LoRusso, Patricia, Ma, Cynthia, Miller, Kathy D, Molnár, István, Moyo, Victor, Munster, Pamela, Reynolds, Joseph, Shields, Anthony F, Siegel, Barry A, Wickham, Thomas J   +14 more
core   +2 more sources

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Future Oncology, 2020
Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal ...
H. Chung, Y. Bang, Charles S Fuchs, S. Qin, T. Satoh, K. Shitara, J. Tabernero, E. Cutsem, M. Alsina, Z. Cao, Jia Lu, P. Bhagia, C. Shih, Y. Janjigian   +13 more
semanticscholar   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

Journal of Clinical Oncology, 2019
PURPOSE Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive ...
L. Fehrenbacher, R. Cecchini, C. Geyer, P. Rastogi, J. Costantino, J. Atkins, J. Crown, J. Polikoff, J. Boileau, L. Provencher, C. Stokoe, T. Moore, A. Robidoux, P. Flynn, V. Borges, K. Albain, S. Swain, S. Paik, E. Mamounas, N. Wolmark   +19 more
semanticscholar   +1 more source

Target Points in Trastuzumab Resistance [PDF]

International Journal of Breast Cancer, 2012
Epidermal growth factor (EGF) family of receptors is involved in cell growth and differentiation. The human EGF2 (HER2) lacks natural ligands, and correlation between HER2 levels and carcinogenesis makes the receptor an ideal candidate for targeted therapy in breast cancer. Trastuzumab is a humanized antibody applied against HER2-positive breast tumors
Abbas Rahimi Shamabadi, Sahar Shojaei, Mossa Gardaneh   +2 more
openaire   +4 more sources

In Vivo Biosynthesis and Direct Incorporation of Noncanonical Amino Acids into Proteins

ChemBioChem, EarlyView.
This review evaluates engineered (semi)autonomous cell systems for the biosynthesis and incorporation of noncanonical amino acids (ncAAs) into proteins. While semi‐autonomous cells convert supplied precursors into ncAAs autonomous cells integrate biosynthetic pathways that produce these building blocks intracellularly.
Jan Hendrik Illies, Tim Moritz Weber, Ivana Drienovská   +2 more
wiley   +1 more source

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Journal of Clinical Oncology, 2018
Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous ...
A. Fader, D. Roque, E. Siegel, N. Buza, P. Hui, O. Abdelghany, S. Chambers, A. Secord, L. Havrilesky, D. O’Malley, F. Backes, N. Nevadunsky, B. Edraki, D. Pikaart, W. Lowery, K. ElSahwi, P. Celano, S. Bellone, M. Azodi, B. Litkouhi, E. Ratner, D. Silasi, P. Schwartz, A. Santin   +23 more
semanticscholar   +1 more source

Biocompatible Chemistry: A Plug‐and‐Play Toolbox for Chemical Biology Research

ChemBioChem, EarlyView.
The “plug‐and‐play” nature of biocompatible chemistry makes it a powerful toolbox for investigating complicated biological systems and producing drug leads for clinical usages. This review summarizes the commonly used biocompatible reactions and the recent advances of their representative applications in chemical biology research, thus highlighting the
Adam R. Lovato, Zeng Lin, Qingfei Zheng
wiley   +1 more source